Smith & Nephew plc
SNNHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Smith & Nephew plc focuses on Medical Devices services and products. Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company carries a $12.63B market cap, placing it firmly in the large-cap category. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Market Cap
$12.63B
Beta
0.67
P/E (TTM)
20.76
P/E (Fwd)
13.62
EPS (TTM)
$1.43
EPS (Fwd)
$2.18
ROE
11.8%
ROA
5.3%
Cash
$557.0M
Total Debt
$3.33B
Free CF
$876.6M
52W Change
1.8%
Annual Financials
Cash vs Debt
Smith & Nephew plc carries $3.33B in total debt against $557.0M in cash reserves — debt is roughly 6.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $876.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 11.8% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $5.21B to $6.16B.
With a beta below 0.7, Smith & Nephew plc typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Smith & Nephew plc's trajectory.